Ras Gene Mutations in Human Endometrial Carcinoma

Oncology (Switzerland)

Volumn 53, Issue 6, 1996, Pages 505-510

  Varras, Michail N ^a,b   Koffa, Maria ^a,c   Koumantakis, Eugenios ^a   Ergazaki, Maria ^a,c   Protopapa, Eufrosyni ^d   Michalas, Stylianos ^b   Spandidos, Demetrios A ^a,c  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c INSTITUTE OF BIOLOGY   (Greece)

^d METAXA CANCER HOSPITAL   (Greece)

Author keywords

Endometrial lesions; H ras; K ras; N ras; Point mutations; Polymerase chain reaction; Restriction fragment length polymorphism analysis

Indexed keywords

ADULT; ARTICLE; CANCER SURVIVAL; CODON; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE RAS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

CARCINOMA; CODON; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENES, RAS; GREECE; HUMANS; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SURVIVAL RATE;

EID: 0029859397     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227627     Document Type: Article

References (35)

1. Young CR, Fuks Z, Knapp RC, Diaia PJ: Principles and Practice of Oncology; in DcVita VT, Heilman S Jr, Rosenberg SA (eds): Cancer in Ovary, Philadelphia, Lippincott, 1985, pp 1083-1117.
2. Bcrchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarkc-Pcarson DL, Bast RC: Ovcrexprcssion of HFR-2 /neu in endometrial cancer is associated with advanced stage disease, Am J Obstet Gynecol 1991; 164:15-21.
3. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min K-W: Expression of EGFR, HER-2/wh, p53 and PCNA in endometrioid serous papillary and clear cell endometrial adenocarcinomas, Gynecol Oncol 1994:53:84-92.
4. Paik S: Clinical significance of erbB-2 (HER-2/m>«) protein, Cancer Invest 1992:10: 575-579.
5. Borst MP, Baker VV, Dixon D, Hatch KD, Shingleton HM, Miller DM: Oncogene alteration in endometrial carcinoma, Gynecol Oncol 1990;38:364-366.
6. Leiserowitz GS, Harris SA, Subramaniam M, Keeney GL, Podratz KC, Spelsbcrg TC: The proto-oncogene c-fms is overexpresscd in endometrial cancer, Gynecol Oncol 1993:49:190- 196.
7. Mizuuchi H, Nasim S, Kudo R, Silverbcrg SG, Greenhouse S, Garrett CT: Clinical Implications of K-ras mutations in maligmant epithelial tumors of the endometrium, Cancer Res 1992;52:2777-2781.
8. Bates NP, Hunrst HC: Basic gene expression in cancer: in Leake R, Gore M, Ward RH (eds): The Biology of Gynaecological Cancer, London, RCOG Press, 1995, pp 11-18.
9. Kiaris H, Spandidos DA: Mutations of ras genes in human tumours (review), Int J Oncol 1995:7:413-421.
10. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ: p53 and Kiras gene mutations in epithelial ovarian neoplasmas, Cancer Res 1993;53:3103-3108.
11. Lester DR, Cauchi MN: Point mutations at codon 12 of c-K-ras in human endometrial carcinomas, Cancer Lett 1990:51:7-10.
12. Enomoto T, Inoue M, Pcrantoni AO, Tcrakawa N, Tanizawa O, Rice JM, K-ras activation in neoplasms of human female reproductive tract, Cancer Res 1990;50:6139-6145.
13. Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, Rice JM: K-ras activation in premalignant and malignant epithelial lesions of the human uterus, Cancer Res 1991;51:5308-5314.
14. Sato S, Ito K, Ozawa N, Yajima A, Sasano H: Analysis of point mutations at codon 12 of K-ras in human endometrial carcinoma and cervical adenocarcinoma by dot blot hybridization and polymerase chain reaction, Tohoku J Exp Med 1991;165:131-136.
15. Ignar-Trowbridgc D, Risinger JI, Dent GA, Kohler M, Berchuck A, McLachlan JA, Boyd J: Mutations of the Ki-ras oncogene in endometrial carcinoma, Am J Obstet Gynecol 1992; 167:227-232.
16. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Tcrashima Y, Sicgal GP, Parker SL, Kohler MF, Berchuck A, Boyd J: Mutation of the Ki-ras protooncogenc in human endometrial hyperplasia and carcinoma, Cancer Res 1993;53:1906-1910.
17. Duggan BD, Felix JC, Mudcrspach LI, Tsao JL, Shibata DK: Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma, Cancer Res 1994:54:1604-1607.
18. Spandidos DA, Liloglou T, Arvanitis D, Gourt-soyiannis NC: ras gene activation in human small intestinal tumors, Int J Oncol 1993;2: 513-518.
19. Poulsen HE, Taylor CW, Sobin LH: International histological classification of tumours no 13; in World Health Organization Histological typing of female genital tract tumors, Geneva, 1975, p 64.
20. Quinn MA, Anderson MC, Coulter CAE: Malignant disease of the uterus: in Shaw R, Souttcr P, Stanton S (eds): Gynaecology, Edinburgh, Churchill Livingstone, 1992, pp 533-555.
21. Burke TW, Morris M: Surgery for malignant tumors of the uterine corpus; in Gcrshenson DM, De Chcmcy AH, Curry SL (eds): Operative Gynecology, Philadelphia, Saunders, 1993, pp 371-393.
22. FIGO stages revision, Gynecol Oncol 1989:35: 125-127.
23. Fujimoto I, Shimizu Y, Hirai Y, Chen JT, Teshima H, Hasumi K, Masubuchi K, Takahashi M: Studies on ras oncogene activation in endometrial carcinoma, Gvnccol Oncol 1993; 48:196-202.
24. Koffa M, Koumantakis E, Ergazaki M, Mala-mou-Mitsi V, Spandidos DA: Detection of ras gene mutations and HPV lesions of the human female reproductive tract, Int J Oncol 1994:5: 189-195.
25. Silini EM, Bosi F, Pcllegata NS, Volpato G, Romano A, Nazari S, Tinelli C, Ranzani GN, Solcia E, Fiocca R: K-ras gene mutations: An unfavorable prognostic marker in stage I lung adenocarcinoma, Virchows Arch 1994,424: 367-373.
26. Benhattcr J, Losi L, Chaubert P, Givcl JC, Costa J: Prognostic significance of K-ra.s mutations in colorectal carcinoma, Gastroenterology 1993;104:1004-1008.
27. Caldas C, Hahn SA, Hruban RH, Rcdston MS, Yco CJ, Kern SE: Detection of K-ras mutations in the stools of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia, Cancer Res 1994:54:3568-3573.
28. Enomoto T, Fujita M, Inoue M, Nomura T, Shroyer KR: Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado, Am J Clin Pathol 1995; 103: 224-230.
29. Caduff RF, Johnston CM, Frank TS: Mutations of the Ki-ra.s oncogene in carcinoma of the endometrium, Am J Pathol 1995:146:182- 188.
30. Enomoto T, Fujita M, Inoue M, Rice JM, Nakajima R, Tanizawa O, Nomura T: Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ra.v-2 proto-oncogene in premalignant and malignant lesions of the human uterine endometrium, Cancer Res 1993;53:1883-1888.
31. Liu E, Hjelle B, Morgan R, Hecht F, Bishop JM, Mutations of the Kirsten-ras proto-onco-genein human preleukemia, Nature 1987;330: 186-188.
32. Leon J, Kamimo H, Steinberg JJ, Pellicer A: H-ras activation in benign and self-regressing skin tumors (keratoacanthomas) in both humans and an animal model system, Mol Cell Biol 1988;8:786-793.
33. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, Wynford-Thomas D: High frequency of ras oncogene mutation in all stages of human thyroid tumorigcnesis, Oncogene 1989,4:159-164.
34. Vogclstein B, Fearon ER, Hamilton SR, Kerns E, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL: Genetic alterations during colorcctal-tumor development N Engl J Med 1988:319:525-532.
35. Scarpa A, Capelli P, Villaneuva A, Zamboni G, Luis F, Accolla R, Mariuzzi G, Capella G: Pancreatic cancer in Europe: K-ras gene mutation pattern shows geographical differences, Int J Cancer 1994;57:167-171.